IV Sodium Ferric Gluconate Complex in Patients Undergoing TAVI

Summary

Iron deficiency is common among patients undergoing TAVI. It is estimated at 54-79%. Previous non-randomized small trial have shown symptomatic benefit in treating iron deficiency in this group of patients. The investigators predict, that as IV iron will improve symptoms, quality of life and exercise tolerance in this group of patients.

Timeline

Start

2020-10-18

Primary completion

2024-10-31

Completion

2024-10-31

Publications

• Bar O, Zukermann R, Halhal B, Marcusohn E. The effect of intravenous sodium ferric gluconate complex (Ferrlecit) on outcomes of patients undergoing transcatheter aortic valve implantation: a prospective randomized controlled trial. J Cardiovasc Med (Hagerstown). 2026 May 1;27(5):389-397. doi: 10.2459/JCM.0000000000001867. Epub 2026 Mar 17.

Drugs

Indications